{"id":40104,"date":"2018-12-19T16:46:36","date_gmt":"2018-12-19T15:46:36","guid":{"rendered":"https:\/\/www.fedaiisf.it\/?p=40104"},"modified":"2018-12-19T19:50:20","modified_gmt":"2018-12-19T18:50:20","slug":"svizzera-novartis-propone-una-revisione-per-i-prezzi-dei-farmaci","status":"publish","type":"post","link":"https:\/\/www.fedaiisf.it\/en\/svizzera-novartis-propone-una-revisione-per-i-prezzi-dei-farmaci\/","title":{"rendered":"Swiss. Novartis Proposes Overhaul for Drug Pricing"},"content":{"rendered":"<h4>CEO Vas Narasimhan does not rule out staggered payments for the most expensive treatments, or their reimbursement in case of insufficient effectiveness<\/h4>\n<p><a href=\"https:\/\/www.tio.ch\/svizzera\/economia\/1342172\/novartis-propone-una-revisione-per-i-prezzi-dei-farmaci\" target=\"_blank\" rel=\"noopener\">tio ch \u2013 December 19, 2018<\/a><\/p>\n<p>BASEL \u2013 Novartis CEO Vas Narasimhan today called for a major overhaul of drug pricing mechanisms. Through the pages of the &quot;Handelszeitung&quot; it does not exclude staggered payments for the most expensive treatments, or their reimbursement in case of insufficient effectiveness.<\/p>\n<p>The measures could concern, for example, Kymriah gene therapy. Approved in Switzerland at a cost of 370,000 francs per treatment, it is intended for children and adults suffering from specific forms of leukemia.<\/p>\n<p>Novartis also recently made no secret of its ambitions to price the experimental gene treatment Zolgensma (AVXS-101), aimed at combating spinal muscular atrophy type one, at over one million. Developed by the American laboratory Avexis, it was acquired last May for 9 billion dollars (about 8.92 billion francs).<\/p>\n<p>&quot;The health system can hardly neglect vital treatments,&quot; said the CEO of the pharmaceutical giant, underlining the need for a rethought dialogue between the parties involved.<\/p>","protected":false},"excerpt":{"rendered":"<p>Il CEO Vas Narasimhan non esclude pagamenti scaglionati per i trattamenti pi\u00f9 onerosi, o il loro rimborso in caso di efficacia insufficiente tio ch &#8211; 19 dicembre 2018 BASILEA &#8211; Il CEO di Novartis, Vas Narasimhan, ha chiesto oggi una revisione profonda dei meccanismi riguardanti i prezzi dei farmaci. Attraverso le pagine della &#8220;Handelszeitung&#8221; non &hellip;<\/p>","protected":false},"author":4,"featured_media":2948,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-40104","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizie"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/40104","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/comments?post=40104"}],"version-history":[{"count":0,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/40104\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media\/2948"}],"wp:attachment":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media?parent=40104"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/categories?post=40104"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/tags?post=40104"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}